FDA May Defer Review Of Amendments Under "Complete Response" Reg
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s proposed "complete response" regulation gives the agency the discretion to defer review of an amendment until a subsequent review cycle.